Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group (Q33385371)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group |
scientific article |
Statements
1 reference
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group (English)
1 reference
Hartmut Döhner
1 reference
Thorsten Zenz
1 reference
Michael Hallek
1 reference
Dirk Winkler
1 reference
Andreas Bühler
1 reference
Richard F Schlenk
1 reference
Silja Groner
1 reference
Raymonde Busch
1 reference
Manfred Hensel
1 reference
Ulrich Dührsen
1 reference
Jürgen Finke
1 reference
Peter Dreger
1 reference
Ulrich Jäger
1 reference
Eva Lengfelder
1 reference
Ulrike Söling
1 reference
Rudolf Schlag
1 reference
Michael Kneba
1 reference
German Chronic Lymphocytic Leukemia Study Group
1 reference
13 July 2009
1 reference
1 reference
27
1 reference
24
1 reference
3994-4001
1 reference
Identifiers
1 reference
1 reference